The US Food and Drug Administration (FDA) on Friday released draft guidance for sponsors developing stimulant drugs for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric and adult patients. FDA explains how ADHD is a common neurobehavioral disorder with onset in childhood. Stimulant drugs (e.g., methylphenidate, amphetamine) are the most commonly prescribed medications for treatment of ADHD, the agency said.